他汀类药物在治疗非酒精性脂肪肝病中的研究进展  

Research progress of statins in the use of nonalcoholic fatty liver disease

作　　者：陈思[1] 赵金珍[1] 胡晶[1] 银孟卓[1] 郭志刚[1] 

机构地区：[1]南方医科大学南方医院惠侨医疗中心,广东省广州市510515

出　　处：《中国动脉硬化杂志》2017年第3期297-303,共7页Chinese Journal of Arteriosclerosis

基　　金：国家自然科学基金面上项目(81370380);广东省自然科学基金面上项目(s2013010014739);广东省教育厅省级重大项目(2014KZDXM020);广州市科技计划科学研究专项一般项目(201510010090)

摘　　要：近年来,非酒精性脂肪肝病逐渐成为国内肝病相关死亡率的主要因素。非酒精性脂肪肝病的发病机制主要与代谢综合征相关,其危险因素主要包括肥胖、2型糖尿病、脂代谢异常等,这些危险因素与心血管疾病密切相关,心血管疾病死亡率也成为非酒精性脂肪肝病首要的死亡原因。他汀类药物是最主要的降脂药物,有证据表明,非酒精性脂肪肝病患者使用他汀类药物降脂治疗不仅能有效降低肝脏转氨酶水平,降低心血管疾病病死率,而且能有效减轻肝脏脂肪变性程度,同时可能对延缓肝脏纤维化有一定的疗效。In recent years, nonalcoholic fatty liver disease has gradually become the main factor of liver-related mortality in China. The pathogenesis of nonalcoholic fatty liver disease mainly associates with the metabolic syndrome and its risk factors include obesity, type 2 diabetes, abnormal lipid metabolism, etc. These risk factors are closely related to the cardiovascular disease. Therefore, the cardiovascular mortality has become a primary cause of death in nonalcoholic fatty liver disease. Statins are the main lipid-lowering drugs. There is evidence that nonalcoholic fatty liver disease patients using statins not only can effectively reduce the liver transaminase level and the mortality of cardiovascular disease, but also can effectively improve hepatic steatosis, and may delay progression of liver fibrosis.

关 键 词：他汀类药物 非酒精性脂肪肝病 心血管疾病 肝脂肪变性 肝纤维化 

分 类 号：R5[医药卫生—内科学]